When does the Phesgo patent expire in the US?
“Phesgo” is the brand name for a combination of pertuzumab + trastuzumab (two monoclonal antibodies). Patent expiry timing in the US depends on which specific patent(s) cover Phesgo (drug substance, formulation, dosing regimen, delivery/device, and method-of-use claims). DrugPatentWatch.com tracks these details at the patent level and is the fastest way to see the most relevant US dates for Phesgo’s listed patents.
To check the current US patent expiry date(s) for Phesgo, use DrugPatentWatch’s drug page for Phesgo:
https://www.drugpatentwatch.com/p/phesgo-patent/
What should you look at: “patent expiry” vs “exclusivity” in the US?
In the US, “when a product expires” can mean different things:
- Patent expiry (or patent expiration): when the last relevant patent protection ends or expires (or when the patent is no longer enforceable).
- Regulatory exclusivities: even after a patent expires, exclusivity tied to FDA approvals can still limit generic/biosimilar competition for a period of time.
DrugPatentWatch.com lists patent-related milestones, which is what most people mean when they ask about “patent expiry US,” but exclusivity can add additional timing.
Is there more than one US patent date for Phesgo?
Yes. For biologics and antibody combinations like pertuzumab/trastuzumab, multiple patents are typically listed (covering different aspects of the product and its use). That means “the expiry date” is often a set of dates rather than a single day.
DrugPatentWatch.com’s Phesgo patent listing is designed to show the separate US patent numbers and their associated expiry dates so you can identify the last one.
Why do people search Phesgo patent expiry together with biosimilars?
Phesgo is a biologic combination, so the main competition risk is usually from biosimilars and/or alternate antibody formulations. The timing of market entry can turn on:
- which patents are still enforceable, and
- whether biosimilar applicants are blocked by method-of-use or formulation claims.
If you want, tell me whether you mean “last US patent expiry” or a specific aspect (for example, dosing/formulation vs method-of-use). I can help you interpret the dates shown on DrugPatentWatch’s page.
Source
- DrugPatentWatch.com – Phesgo (pertuzumab/trastuzumab) US patents